We read the interim analysis from the REGARD study, in which the Chari et al1 used laboratory glycemic data to define glycemically defined new-onset diabetes (GNOD) in adults aged 50 years of age and older and then quantified the 3-year risk of pancreatic cancer. This work anchors risk on a clear timeline and offers real-world evidence for using GNOD as an entry point for early detection. A few signals, however, could be brought to the foreground to make bedside risk discussions and downstream trial design more straightforward.
Gastroenterology (AGA) published a clinical update in Research Highlights on 21 Feb 2026.
The item focuses on Time-Anchored Risk After Glycemically Defined New-Onset Diabetes and Its Implications for Pancreatic Cancer Detection.
Review the original article for the full source wording and details.